| editorial | Q871232 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jürgen Floege | |
| Vincent M Brandenburg | |||
| P2860 | cites work | Development of low-turnover bone diseases after parathyroidectomy and autotransplantation | Q74507715 |
| Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients | Q74526361 | ||
| Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes | Q76378411 | ||
| Hypokinetic azotemic osteodystrophy | Q77291614 | ||
| Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis | Q79629072 | ||
| Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study | Q80025037 | ||
| Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol | Q80051171 | ||
| Variant of adynamic bone disease in hemodialysis patients: fact or fiction? | Q80164218 | ||
| A sensitive stain for aluminum in undecalcified cancellous bone | Q80703400 | ||
| The evolution of assays for parathyroid hormone | Q80994757 | ||
| Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry | Q81072140 | ||
| Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome | Q81470493 | ||
| Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors | Q81550347 | ||
| Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 | ||
| Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy | Q28331992 | ||
| Circulating biochemical markers of bone remodeling in uremic patients | Q33650293 | ||
| Calcific uremic arteriolopathy in association with low turnover uremic bone disease | Q33739655 | ||
| Low bone turnover in patients with renal failure | Q33816230 | ||
| Pathogenesis, prevention and management of low-bone turnover. | Q34080041 | ||
| Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function | Q57226014 | ||
| Renal osteodystrophy in diabetic patients | Q57226097 | ||
| Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining | Q67898005 | ||
| Risk of adynamic bone disease in dialyzed patients | Q67909470 | ||
| Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers | Q67937392 | ||
| Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity | Q68349802 | ||
| Bone histomorphometry of renal osteodystrophy in diabetic patients | Q68718310 | ||
| Effect of aluminum on parathyroid hormone secretion | Q68724038 | ||
| The natural course of dialysis osteomalacia | Q68724062 | ||
| Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH | Q68724079 | ||
| Bone histologic response to deferoxamine in aluminum-related bone disease | Q68999921 | ||
| Early therapy of renal bone disease with calcitriol: a prospective double-blind study | Q69575482 | ||
| Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure | Q70053175 | ||
| The spectrum of bone disease in end-stage renal failure--an evolving disorder | Q70580279 | ||
| Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis | Q70622955 | ||
| Parathyroid and bone response of the diabetic patient to uremia | Q70624749 | ||
| Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload | Q70980348 | ||
| Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study | Q71163832 | ||
| Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients | Q71612719 | ||
| The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy | Q71861178 | ||
| Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH | Q71964275 | ||
| The role of bone biopsy in the management of patients with renal osteodystrophy | Q72016390 | ||
| Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy | Q72559006 | ||
| Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy | Q72749657 | ||
| Evidence for abnormal calcium homeostasis in patients with adynamic bone disease | Q72898122 | ||
| Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro | Q73010564 | ||
| The relationship between basic multicellular unit activation and origination in cancellous bone | Q73211279 | ||
| Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone | Q73235636 | ||
| Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia | Q73457000 | ||
| Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate | Q74081683 | ||
| Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD | Q74130880 | ||
| Different patterns of renal osteodystrophy in Iberoamerica | Q74300117 | ||
| Risk factors for vertebral fractures in renal osteodystrophy | Q74451547 | ||
| Harnessing the parathyroids to create stronger bones | Q34327185 | ||
| Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats | Q34433399 | ||
| The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism | Q34521914 | ||
| The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? | Q34547601 | ||
| Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients | Q34622644 | ||
| Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry | Q35157959 | ||
| Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy | Q35674615 | ||
| Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. | Q36001509 | ||
| New insights into mineral and skeletal regulation by active forms of vitamin D. | Q36366492 | ||
| Development of renal bone disease. | Q36554767 | ||
| Diagnosis of renal osteodystrophy | Q36554773 | ||
| Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients | Q36677395 | ||
| Metabolic bone disease in chronic kidney disease | Q36717712 | ||
| Vascular calcification and disordered mineral metabolism in dialysis patients | Q36765024 | ||
| Vascular calcification and fetuin-A deficiency in chronic kidney disease | Q36812086 | ||
| Mineral metabolism disturbances in patients with chronic kidney disease | Q36884206 | ||
| Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure | Q36902283 | ||
| Aluminium-induced bone disease in uremic rats: effect of deferoxamine | Q39261811 | ||
| Aluminum and renal osteodystrophy | Q39588926 | ||
| Aluminium toxicity in chronic renal insufficiency | Q39834440 | ||
| Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients | Q40684299 | ||
| Low turnover bone disease. | Q41052453 | ||
| Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure | Q41727962 | ||
| Effect of aluminium load on parathyroid hormone synthesis. | Q43556762 | ||
| Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation | Q43812641 | ||
| Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients | Q43904863 | ||
| Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. | Q44015516 | ||
| Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients | Q44039636 | ||
| The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia | Q44135485 | ||
| Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients | Q44423486 | ||
| Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis | Q44441928 | ||
| Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure | Q44445022 | ||
| A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients | Q44445038 | ||
| Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. | Q44582481 | ||
| Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice | Q44592811 | ||
| Arterial calcifications and bone histomorphometry in end-stage renal disease | Q44949005 | ||
| Activated injectable vitamin D and hemodialysis survival: a historical cohort study | Q45281077 | ||
| Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients | Q46122319 | ||
| Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings | Q46281986 | ||
| Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis | Q46433510 | ||
| Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density | Q46522344 | ||
| Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. | Q46572840 | ||
| K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. | Q46815338 | ||
| Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease | Q46945387 | ||
| Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure | Q48031884 | ||
| The dialysis encephalopathy syndrome. Possible aluminum intoxication | Q48406833 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| Differences in calcium kinetic pattern between CAPD and HD patients. | Q51040180 | ||
| PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. | Q53607251 | ||
| Hyperaluminaemia from aluminum resins in renal failure. | Q53753011 | ||
| Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. | Q53970602 | ||
| Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. | Q54035070 | ||
| Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD | Q54520114 | ||
| Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium | Q57221130 | ||
| Low-calcium dialysate improves mineral metabolism in hemodialysis patients | Q57221542 | ||
| Reversal of adynamic bone disease by lowering of dialysate calcium | Q57221775 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 135-147 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | NDT Plus | Q15750624 |
| P1476 | title | Adynamic bone disease-bone and beyond | |
| P478 | volume | 1 |
| Q37298652 | (18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease |
| Q57217513 | Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure |
| Q34572435 | Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. |
| Q38511621 | Contemporary management of phosphorus retention in chronic kidney disease: a review |
| Q36267767 | Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients |
| Q37912038 | Diseases of the parathyroid gland in chronic kidney disease. |
| Q28535084 | Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin? |
| Q57214386 | Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers |
| Q59051207 | Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management |
| Q42688826 | Management of adynamic bone disease in chronic kidney disease: A brief review |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q53811045 | Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. |
| Q39014553 | Osteoporosis in patients with diabetes after kidney transplantation |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q37015581 | Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India |
| Q58715560 | Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care |
| Q38359423 | Sclerostin and CKD-MBD. |
| Q33779709 | Skeletal effects of zoledronic acid in an animal model of chronic kidney disease |
| Q58765036 | Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy |
| Q54917687 | Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. |
| Q36801566 | Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes |
Search more.